Conclusions
JDM
REGRESSION, RECRUITMENT, CURB
In this pilot RCT comparing the Pivot and QuitGuide mobile smoking cessation programs, Pivot had higher abstinence rates at 52 weeks. The context of this outcome in a study powered for engagement underscores the effectiveness of the intervention. Moreover, the treatment effect was durable, with stable biovalidated continuous abstinence rates from 26 to 52 weeks. This study adds to the small but growing body of RCT-derived evidence focused on longer-term outcomes among adult smokers using mobile smoking cessation programs. The data are encouraging and consistent, pointing to an important role for these types of programs in the larger effort to curb nicotine dependence.The authors thank Alex Kolodychak for his direct role in the recruitment and collaborative tracking of study participants.Authors' Contributions: JDM, CAF, DJB, and DSU designed the study. JDM, CAF, and MTU recruited participants. JDM and DJB oversaw the study. CAF managed the database. CAF and JAG determined the most appropriate analyses and performed them. MTU performed many of the functions of study conduct, including managing participant interactions, data collection, participant compliance with questionnaires and visits, scheduling and running of biovalidation visits, and study payments. CAF and JDM assisted with the aforementioned study conduct tasks as needed. JDM, MTU, and CAF prepared the original draft of the manuscript. JDM, CAF, MTU, DJB, DSU, and JAG reviewed and edited the manuscript before submission.Conflicts of Interest: JDM, CAF, MTU, DJB, and DSU are current employees of Pivot Health Technologies Inc (Pivot), the developer of the Pivot smoking cessation program. They receive salary and stock options from Pivot. DSU is the president and chief executive officer of Pivot and an investor in the company. JAG is a paid statistical consultant.Intention-to-treat (N=188) logistic regression analyses of baseline predictors of 7-day point-prevalence abstinence (PPA), 30-day PPA, biovalidated PPA, continuous abstinence, and biovalidated continuous abstinence at 52 weeks among all study participants.CONSORT-EHEALTH Checklist (V 1.6.1).